Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Boehringer Ingelheim
Healthtrust
Covington
AstraZeneca
Moodys
McKinsey
Deloitte
Mallinckrodt

Generated: January 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,633,309

« Back to Dashboard

Summary for Patent: 8,633,309
Title:Nucleoside phosphoramidates
Abstract: Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
Inventor(s): Ross; Bruce (El Granada, CA), Sofia; Michael Joseph (Doylestown, PA), Pamulapati; Ganapati Reddy (San Ramon, CA), Rachakonda; Suguna (Twinsburg, OH), Zhang; Hai-Ren (San Jose, CA), Chun; Byoung-Kwon (Robbinsville, NJ), Wang; Peiyuan (Totowa, NJ)
Assignee: Gilead Pharmasset LLC (Foster City, CA)
Application Number:13/738,425
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 8,633,309

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Gilead Sciences Inc EPCLUSA sofosbuvir; velpatasvir TABLET;ORAL 208341-001 Jun 28, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y FOR THE TREATMENT OF HEPATITIS C ➤ Subscribe
Gilead Sciences Inc HARVONI ledipasvir; sofosbuvir TABLET;ORAL 205834-001 Oct 10, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y FOR THE TREATMENT OF HEPATITIS C ➤ Subscribe
Gilead Sciences Inc SOVALDI sofosbuvir TABLET;ORAL 204671-001 Dec 6, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y FOR THE TREATMENT OF HEPATITIS C ➤ Subscribe
Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir TABLET;ORAL 209195-001 Jul 18, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,633,309

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,563,530 Purine nucleoside phosphoramidate ➤ Subscribe
9,206,217 Nucleoside phosphoramidates ➤ Subscribe
8,735,569 Nucleoside phosphoramidates ➤ Subscribe
9,637,512 Nucleoside phosphoramidates ➤ Subscribe
8,859,756 Stereoselective synthesis of phosphorus containing actives ➤ Subscribe
8,618,076 Nucleoside phosphoramidates ➤ Subscribe
8,629,263 Nucleoside phosphoramidates ➤ Subscribe
8,642,756 Nucleoside phosphoramidates ➤ Subscribe
9,284,342 Nucleoside phosphoramidates ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,633,309

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan I498117 ➤ Subscribe
Taiwan 201136593 ➤ Subscribe
San Marino T201600316 ➤ Subscribe
San Marino T201500285 ➤ Subscribe
Slovenia 2552930 ➤ Subscribe
Slovenia 2432792 ➤ Subscribe
Singapore 10201702294Q ➤ Subscribe
Singapore 10201702025S ➤ Subscribe
Singapore 10201500835W ➤ Subscribe
Singapore 184324 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Deloitte
Cipla
US Army
Healthtrust
Queensland Health
Merck
Fuji
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot